Physician profile
Omar U Farrukh
NPI 1174817373
$3,730.18
in general payments reported to CMS, 2019-2025
24 companies · $1,317 in 2025
The $1,317 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2022: $505 · 2023: $1,121 · 2024: $688 · 2025: $1,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,125.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $707.17 | 2024-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $702.70 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $278.90 | 2022-2023 | |
| Travere Therapeutics, INC. | $268.58 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $246.30 | 2022-2025 | Velphoro, Korsuva, Velphoro |
| Otsuka America Pharmaceutical, INC. | $219.93 | 2022-2025 | Jynarque |
| Horizon Therapeutics Plc | $217.47 | 2022-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $179.93 | 2023-2025 | Acthar |
| Shield Therapeutics INC | $119.10 | 2025 | |
| Alexion Pharmaceuticals, INC. | $115.83 | 2024-2025 | Ultomiris |
| Aurinia Pharma U.S., INC. | $110.46 | 2022-2025 | Lupkynis |
| Vifor Pharma, INC. | $97.78 | 2023-2024 | Veltassa |
| Nxstage Medical, INC. | $74.33 | 2022 | |
| Novartis Pharmaceuticals Corporation | $70.04 | 2023-2025 | |
| Ucb, INC. | $53.08 | 2023-2024 | Rystiggo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $47.64 | 2024-2025 | |
| Glaxosmithkline, LLC. | $43.08 | 2022-2023 | Benlysta |
| Scpharmaceuticals INC. | $40.11 | 2025 | |
| Calliditas Therapeutics US INC. | $37.94 | 2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.04 | 2025 | Jardiance |
| Ardelyx, INC. | $19.35 | 2024 | Ibsrela |
| Apellis Pharmaceuticals, INC. | $18.29 | 2025 | Empaveli |
| Takeda Pharmaceuticals U.S.A., INC. | $15.88 | 2022 | |
| Akebia Therapeutics INC | $14.25 | 2025 | Vafseo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Farrukh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.